To discover original inhibitors of the ubiquitin-proteasome pathway, the authors have developed a cell-based bioluminescent assay and used it to screen collections of plant extracts and chemical compounds. They first established a DLD-1 human colon cancer cell line that stably expresses a 4Ubiquitin-Luciferase (4Ub-Luc) reporter protein, efficiently targeted to the ubiquitinproteasome degradation pathway. The assay was then adapted to 96-and 384-well plate formats and calibrated with reference proteasome inhibitors. Assay robustness was carefully assessed, particularly cell toxicity, and the statistical Z´ factor value was calculated to 0.83, demonstrating a good performance level of the assay. A total of 18,239 molecules and 15,744 plant extracts and fractions thereof were screened for their capacity to increase the luciferase activity in DLD-1 4Ub-Luc cells, and 21 molecules and 66 extracts inhibiting the ubiquitin-proteasome pathway were identified. The fractionation of an active methanol extract of Physalis angulata L. aerial parts was performed to isolate 2 secosteroids known as physalin B and C. In a cell-based Western blot assay, the ubiquitinated protein accumulation was confirmed after a physalin treatment confirming the accuracy of the screening process. The method reported here thus provides a robust approach to identify novel ubiquitin-proteasome pathway inhibitors in large collections of chemical compounds and natural products. (Journal of Biomolecular Screening 2007:106-116) 
INTRODUCTION
P ROTEIN DEGRADATION IS A MAJOR MECHANISM involved in the regulation of cellular processes. There are 2 main protein degradation pathways involving either proteolytic enzymes within the lysosome or the proteolytic core of the ubiquitinproteasome pathway. The 20S proteasome is a ~700-kDa complex formed by 4 rings: 2 inner β rings and 2 outer α rings. The association of the 20S proteasome core particle with 19S regulatory particles forms the 26S proteasome of ~1400 kDa, 1, 2 which is able to degrade ubiquitinated proteins in the presence of adenosine triphosphate (ATP).
Ubiquitination (Ub) is a critically important posttranslational modification that plays major roles in regulating several basic cellular processes such as cell division, differentiation, and signal transduction. 3, 4 Aberrations in the system have been implicated in the pathogenesis of many diseases. 5, 6 Alterations in ubiquitination and deubiquitination reactions have been reported in the etiology of many malignancies, which can result from either stabilization of cancer-promoting factors or destabilization of tumor suppressors. Several ubiquitin-targeted oncoproteins such as Fos/Jun, topoisomerase I, and Bcl-2 can induce malignant transformation if not properly removed from the cell. On the other hand, the destabilization of tumor suppressor proteins such as p53 and p27 has also been implicated in the pathogenesis of several malignancies. 7 Bortezomib (Velcade ® , PS-341, Millenium Pharmaceuticals, Cambridge, MA) is the first proteasome pathway inhibitor approved for use in human cancer patients, 8 particularly the multiple myeloma, confirming the therapeutic value of proteasome inhibition in human malignancy. 9 Ubistatins, a more recently identified ubiquitin-proteasome pathway class of inhibitors, 10 show a different mechanism of action. Ubistatins arrest cell cycle progression by inhibiting cyclin B proteolysis and inhibit the binding of ubiquitinated substrates to the proteasome by targeting the ubiquitin-ubiquitin interface of Lys(48)-linked chains. These chains are also recognized by ubiquitin-chain receptors of the proteasome, indicating that ubistatins act by disrupting a critical protein-protein interaction in the ubiquitin-proteasome system. Natural products have a strong track record as pharmaceuticals. In the domain of the ubiquitin-proteasome pathway, several natural inhibitors have been identified from different origins. Lactacystin, a Streptomyces lactacystinaeus metabolite; 11 salinosporamides, isolated from the marine actinomycete Salinispora tropica; 12, 13 epoxomicin, isolated from an Actinomycetes strain; 14 and the cyclic peptide TMC-95, isolated from the marine endophytic fungus Apiospora montagnei, 15, 16 illustrate the diversity of natural products interfering with the proteasome catalytic activities. Compared to combinatorial chemistry approaches, nature-derived compounds often contain complex structural features covering a more diverse chemical space and therefore offer a great opportunity to discover novel biological activities. However, the purification and resynthesis of naturalorigin molecules is a nonstraightforward and time-consuming process. To accelerate the discovery of biologically active natural compounds, different high-throughput screening (HTS) approaches have been developed. 17, 18 They are mainly based on a primary multisolvent extraction and fractionation of secondary metabolites followed by the biological screening itself. However, these extracts and fractions can potentially interfere in biological screening assays. 19 This could be a "no-go" criterion in an HTS approach where "mix-and-read" interferencesensitive assays are widely used. Methods currently employed to screen proteasome pathway inhibitors are mainly focused on the protease catalytic activity measurement. 20, 21 These homogeneous phase assays are based on the use of fluorescencequenched peptide substrates that produce a fluorescent signal after proteasome cleavage. This procedure could be particularly sensitive to autofluorescence or fluorescence-quenching properties of natural extracts. 22 Moreover, it cannot provide a complete picture of the ubiquitin-proteasome pathway as a global system. The need to develop and validate a robust and HTS-compliant ubiquitin-proteasome pathway assay is then a primary necessity.
The aim of this study was to demonstrate the feasibility of the HTS of large-molecule and natural extract collections with a new bioluminescent assay designed for the discovery of ubiquitinproteasome pathway inhibitors. Active extracts were submitted to an activity-guided fractionation process until pure molecules could be isolated. From 1 of these active extracts, produced from Physalis angulata L. aerial parts, we identified physalin B and C and showed that these compounds could inhibit an endogenous ubiquitinated protein accumulation in cells, confirming the accuracy of the screening-fractionation procedure.
MATERIALS AND METHODS

Reagents and cell culture
Epoxomicin was obtained from Boston Biochem (Cambridge, MA), lactacystin was obtained from Sigma Aldrich (Lyon, France), and bortezomib was synthesized as described elsewhere. 23, 24 The DLD-1 cell line was obtained from the ATCC (Molsheim, France) and cultured at 37 °C in the presence of 5% CO 2 in modified Eagle's medium (MEM; Gibco, Cergy Pontoise, France) containing 5% fetal bovine serum (FBS; Gibco), supplemented with 1.25 µg/mL fungizone (Gibco) and 50 µg/mL streptomycin/penicillin (CambreX, Saint Beauzire, France).
Generation of stably transfected DLD-1 4Ub-Luc and DLD-1 Rf cell lines
The coding region of ubiquitin (Ub) was amplified by RT-PCR with Hela cDNA to introduce 5´ HindIII-NcoI-SpeI and 3´ SacII-BspHI-XbaI restriction sites. The XbaI site allows the mutation of glycine 76 of Ub in valine. This mutation avoids deubiquitination of the ubiquitin residues from the fusion protein. The PCR product was digested with HindII and SacII and ligated into pBluescript II vector (Stratagene, Amsterdam, The Netherlands). This plasmid was then digested with HindIII and BspHI and ligated in pGL-3 vector (Promega, Charbonnieres, France) opened by HindIII and NcoI. Different multimerization was obtained by using NcoI/BspHI and SpeI/XbaI compatibility. The fusion 4Ubluciferase was excised from plasmid pGL-3-4Ub using HindIII and XbaI and cloned in bicistronic vector pRCEN1, previously described 3, 4 in between the cytomegalovirus (CMV) promoter and the IRES-neomycin cassette.
The pRF vector encoding for the wild-type luciferase was obtained from the pRCEN1 vector. The CAT gene was replaced by the luciferase gene excised from the pGL-3 vector using the HindIII-XbaI sites.
These 2 vectors were used to stably transfect DLD-1 cells.
Evaluation of the reporter half-life
Ten-thousand 4Ub-Luc or Luc-expressing DLD-1 cells were pretreated with 100 nM bortezomib or 0.2% DMSO for 5 h. Cycloheximide (100 µM) was then added to block de novo protein synthesis. Cells were collected every 30 min for 4 h. Luciferase activity was measured in each cell extract using a LB Centro ® luminometer (Berthold, Thoiry, France) and was expressed as relative luminescent units (RLUs).
Ubiquitin-proteasome pathway inhibition assay: 96-well format
A first 96-well version of the assay was developed and performed as the following. DLD-1 4Ub-Luc cells were trypsinized Bioluminescence Screening of Ubiquitin-Proteasome Pathway Inhibitors and resuspended with MEM/5% FBS and transferred at a 10,000cell density (100 µL) into 96-well white cell culture plates (PerkinElmer, Courtaboeuf, France). Cells were incubated at 37 °C in a CO 2 incubator for 24 h. Extracts or fractions or chemical compounds were added to the media to a final volume of 110 µL. After a 7-h incubation, the medium was removed, cells were washed twice with 100 µL of phosphate-buffered saline (PBS), and 50 µL of Passive Lysis Buffer (Promega, Charbonnieres, France) was added and the plate was frozen at -20 °C overnight. After thawing, 100 µL of the Luciferase Assay System (Promega) was added, and luminescence was read using an Envision ® plate reader (PerkinElmer). This large-volume assay version was used to test low sample numbers as in hit confirmation and extract fractionation processes.
Ubiquitin-proteasome pathway inhibition assay: 384-well format
The 96-well assay version was miniaturized to a 384-well version, which was used for the automated screening. DLD-1 4Ub-Luc cells were trypsinized and resuspended with MEM/5% FBS and transferred at 5000 cells per well density (50 µL) into 384well white cell culture plates (PerkinElmer). Cells were incubated at 37 °C in a CO 2 incubator for 24 h. Then, 5.5 µL of extracts or fractions or chemical compounds was added to the media. After 7 h of incubation, medium was removed, cells were washed with 50 µL of PBS, and 50 µL of luciferase substrate (Bright Glo Luciferase™, Promega) was added. Luminescence was measured using an Envision ® plate reader (PerkinElmer).
MTT toxicity assay
Cytotoxicity studies were performed using the 3-(4,5dimethylthiazol-2-yl)-2.5-diphenyl-2H-tetrazolium bromide (MTT) assay. DLD-1 4-Ub-Luc cells (1 × 10 4 ) were cultured in 96-well plates during 24 h and treated with different concentrations (40, 20, 10, 5, 2.5, and 1 µg/mL) of P. angulata L. extracts for 7 h. Then, the medium was removed, and 100 µL of MTT reagent (1 mg/mL in Roswell Park Memorial Institute [RPMI]-1640 medium without phenol red and serum) was added. After another 3 h, medium was removed, and 100 µL of DMSO was added. Absorbance was determined with a Fluostar ® plate reader (BMG Technologies, Champigny/Marne, France) at 570 nm. The background was measured at 630 nm and was deducted from the specific signal.
The collection of plants
The collection of plants was constituted on the basis of botanical diversity, assuming that it would generate chemical diversity. Plants originated from the entire world and were collected under the framework of the International Convention on Biological Diversity (Rio de Janeiro, 1992). 25 Several thousand plants, collected over the past 10 years, are thus available for screening when possible, the different parts of the plants were segregated. Plant extracts were standardized in DMSO at the concentration of 50 µg/mL.
In the course of this work, a methanolic extract of P. angulata L. (Solanaceae) has revealed the initial biological activity.
Extract and compound screening
The screening was carried out in the 384-well plate assay version on a Beckman Coulter (Villepinte, France) Core System, including a 3-D ORCA robotic arm, a 384 pipetting station, plate carousels, a plate washer, multidrops, a plate multimode reader, and a temperature-, CO 2 -, and hygrometrycontrolled incubator. The station was controlled by the SAMI 3.5 scheduling software.
Pure compounds were distributed over forty-nine 384-well plates. Each plate contained 384 samples. For quality control, 8 plates containing 0.2% DMSO and various concentrations of epoxomicin were inserted in the run. Compounds were stored at -20 °C as a 500-µM stock solution in 100% DMSO and extemporaneously diluted to a final concentration of 5 µM in 0.2% DMSO.
Extracts and fractions were distributed over forty-one 384well plates. Each plate contained 384 compounds. For quality control, 8 plates containing 0.2% DMSO and various concentrations of epoxomicin were inserted in the run. Extracts and fractions were stored at -20 °C at 50 mg/mL as a maximum concentration in 100% DMSO and diluted the day of the test to a maximum final concentration of 5 µg/mL.
Hit confirmation
After screening, active extracts and compounds were picked from screening plates, reformatted into a 96-well plate, and tested with the 96-well assay format. Confirmation was repeated 2 times at 2-, 1-, and 0.5-µM final concentrations in 0.2% DMSO for the chemical compounds and 10-, 5-, and 2.5-µg/mL maximum final concentrations for extracts and fractions.
Activity-guided fractionation of P. angulata L. extract P. angulata L. (Solanaceae) is a common annual herb indigenous to many parts of the tropics (Africa, Asia, and the Americas). The air-dried, powdered aerial parts (140 g) were extracted overnight with 1.4 L of methanol at room temperature. The active residue (7.3 g) was suspended in methanol (MeOH)/H 2 O and then extracted 3 times with cyclohexane. The MeOH/H 2 O extract was partitioned between H 2 O and ethylacetate (EtOAc). The EtOAc layer was concentrated in a vacuum to give 1.3 g of a residue, which was chromatographed over silica gel. The column was eluted with dichloromethane-MeOH to obtain 2 active fractions. These fractions were purified by semipreparative high-performance liquid chromatography (HPLC) on reverse-phase RP-18 (H 2 O-acetonitrile gradient system) to give 2 compounds that later showed activity.
All extracts and fractions thereof were tested using the 96-well assay version. They were resuspended in 100% DMSO to a concentration of 30 mg/mL, diluted in MEM/5% FBS, and added to the assay media at final concentrations of 10-, 5-, and 2.5-µg/mL.
Structural determination of physalin B and C
Compounds were identified by mass spectrometry (MS) and nuclear magnetic resonance (NMR) experiments and by comparison to analytical data in the literature. 26 
Data analysis
The Z´ factor was calculated according to the method developed by Zhang 
Ubiquitin accumulation electrophoresis
DLD-1 4Ub-Luc cells were treated with various concentrations of physalin B and C (1-10 µM) or epoxomicin at 100 nM for 16 h. After 2 PBS washes, cells were harvested and cell extracts were analyzed by Western blot using an antiubiquitin antibody (Santa Cruz, Heidelberg, Germany).
RESULTS
Validation of the stably transfected DLD-1 4Ub-Luc cell line
We established a DLD-1 human colon cancer cell line that stably expressed a 4Ub-Luc reporter protein efficiently targeted to the ubiquitin-proteasome degradation pathway. To confirm that this increase in luciferase activity was due to an accumulation of the reporter protein within the cells, we determined the half-life of the 4Ub-luc protein in the presence or absence of proteasome inhibitor and compared it to that of the wild-type luciferase protein (Fig. 1) . The luciferase protein was stable with the DLD-1 cells for more than 4 h, whereas the fusion protein 4Ub-Luc showed a half-life of 30 min. As expected, upon treatment with reference proteasome inhibitor, the half-life of the reporter protein was similar to that of the unfused luciferase. This result indicated that the 4Ub-Luc is an efficient target of the proteasome.
Miniaturization of the ubiquitin-proteasome pathway assay in the 384-well plate screening format
The effect of DLD-1 4Ub-Luc cell number per well was first evaluated to generate an optimized luminescent signal. For this, we added various cell amounts, from 10,000 to 1250 per well, in a 384-well plate and incubated them with 500 nM epoxomicin or 0.2% DMSO (Fig. 2) . The measured luciferase signal was significantly higher in the presence of epoxomicin for each cell condition (signal/background > 70). Taking into account the assay robustness, the cell preparation logistic, and the signal-to-background ratio, calculated as the ratio of the signal with 500 nM epoxomicin on the signal with 0.2% DMSO, we decided to work with 5000 cells per well. In this condition, the Z´ factor was calculated to 0.83.
As all of our compound and extract collections were dissolved in DMSO, we checked the DMSO tolerance of the assay on both signal (500 nM epoxomicin) and background (no epoxomicin). Results indicated that DMSO does not affect the signal-tobackground ratio for percentages lower than 1% (data not shown). In the screening experiments, the DMSO percentage was fixed to a 0.2% value.
We then evaluated the specificity of the assay with the reference compound epoxomicin. In the DLD-1 Rf cell line, in which the nonubiquitinated luciferase cannot be addressed to the proteasome pathway, a maximal signal amplification is observed either with 500 nM epoxomicin or with 0.2% DMSO treatments (Fig. 3) . In the DLD-1 4Ub-Luc cell line, very little luciferase signal is observed in the presence of 0.2% DMSO (background) compared to the signal measured in the presence of 500 nM of epoxomicin ( Fig. 3) . Taken together, these results indicate that the epoxomicin-related signal variation observed in the DLD-1 4Ub-Luc cell line can be associated with the ubiquitin-proteasome pathway inhibition. The coefficients of variation (CVs) of the signals measured with 500 nM of epoxomicin or 0.2% DMSO were 2.4% and 6.6%, respectively, in the DLD-1 4Ub-Luc cell line, and the signal-to-background ratio was calculated to be 75. Then both assay precision and sensitivity were satisfying.
To investigate the assay accuracy, several reference compounds other than epoxomicin were tested, including other well-known proteasome pathway inhibitors such as lactacystin and bortezomib (Fig. 4) . Proteasome pathway-unrelated molecules such as monastrol, a kinesin EG5 inhibitor, 29 and etoposide, a topoisomerase II inhibitor, 30 were tested to assess assay specificity. The calculated EC 50 (effective concentration for which the measured luminescent signal represents 50% of the epoxomicin-stimulated maximum luminescent signal) was 45, 866, and 1 nM for epoxomicin, lactacystin, and bortezomib, respectively, indicating that these compounds present a high potency in this assay. As expected, both monastrol and etoposide were found to be inactive up to 10 µM (data not shown). 
Chemical compound and extract toxicity assessment
To evaluate the putative toxic effect of chemical compounds, we first evaluated the effect of high concentrations of epoxomicin on the luciferase signal generated by the DLD-1 4Ub-Luc cells in the 384-well assay format (Fig. 5) . For epoxomicin concentrations superior to 1 µM, we observed a significant signal decrease that was correlated to a cell toxic effect observed in an MTT assay (Fig. 5) .
We then determined the level of signal interferences generated by a set of our natural substances on the DLD-1 4Ub-Luc luciferase activity in the 384-well assay version. To easily detect a significant signal interference, this experiment was done in the presence of 100 nM of epoxomicin, which generated a positive amplification signal. A total of 1536 extracts and fractions were tested at a final concentration of 5 µg/mL. Eight extracts and fractions (0.52%) showed a signal loss below 70% of the 100-nM epoxomicin control.
The putative toxic activity of these 8 extracts was tested by measuring the DLD-1 4Ub-Luc cell viability with the MTT assay. A significant signal decrease was observed with extracts 5, 6, and 7, whereas extracts 1, 2, 3, 4, and 8 were found to be inactive (Fig. 6) .
Screening of pure compound and natural extract collections
The screen was performed on a set of 18,239 different compounds selected to be chemically diverse from the Pierre Fabre Medicament compound library. The set of data obtained with these molecules is shown in Fig. 7A,B . Using a cutoff limit of 4% CTL (99.99% confidence level), we obtained a total of 24 hits, representing a hit rate of 0.13%, with a maximum %CTL of 49.2 (Fig. 7B) .
Data obtained for the screening of the 15,744 natural extracts and fractions, representing 3936 different plants and plant parts (leaf, stem, bark, root, fruit, or whole plant), are shown in Fig. 8A,B . Using the same %CTL cutoff limit (99.99% confidence level), we obtained a total of 77 hits, representing a hit rate of 0.49%, with a maximum %CTL of 43.4 (Fig. 8B) .
In hit confirmation studies, performed 2 times at 3 different concentrations in the same assay, 21 chemical compounds and 66 extracts and fractions were identified, representing confirmation rates of 88% and 85%, respectively.
Activity-guided fractionation of P. angulata L. and structure identification of physalin B and C
We found that a methanolic extract of P. angulata L. showed a significant accumulation of ubiquitinylated luciferase in DLD-1 4Ub-Luc cells. The combination of liquid/liquid extraction and different chromatography purifications (normal and reversedphase liquid chromatography) generated organic phase fractions, from which 2 active compounds were characterized as physalin B and C in agreement with the literature (Fig. 9) .
Determination of the endogenous ubiquitinated protein accumulation inhibition
To confirm that physalin B and C were inhibitors of the ubiquitin-proteasome pathway, we evaluated their ability to induce the accumulation of endogenous ubiquitinated proteins. DLD-1 4Ub-Luc cells were incubated with physalins or epoxomicin, and cell extracts were analysed by Western blot using an antiubiquitin antibody. As expected, dose-dependent accumulation of endogenous ubiquitinated proteins was bserved upon physalin B and C treatment, confirming their ubiquitinproteasome pathway inhibition property (Fig. 10) .
DISCUSSION AND CONCLUSION
Two reporter gene vectors, the 4Ub-Luc and the Rf-Luc, were generated, each containing the luciferase gene reporter. In the 4Ub-Luc gene vector, luciferase gene is associated with the 4ubiquitin gene. These 2 vectors were used to generate 2 distinct DLD-1 reporter cell lines. In the DLD-1 Rf cell line, luciferase is stably expressed, leading to a bioluminescent signal not inhibited by proteasome inhibitors (at subtoxic concentrations). In the DLD-1 4Ub-Luc cell line, the stably expressed 4Ub-Luc reporter protein is rapidly degraded via the ubiquitin-proteasome pathway. Upon addition of luciferin, the luciferase substrate is converted to oxyluciferin, which is a luminescent molecule. Inhibition of the ubiquitin-proteasome pathway involves an accumulation of its luminescent substrate used as criteria for selecting inhibitors.
To validate the use of this reporter assay in the screening of large collections of chemical compounds and natural products, we assessed assay specificity, precision, sensitivity ( Figs. 1-3) , accuracy (Fig. 4) , and robustness, with a particular focus on compound and extract toxicity influence on the screening (Figs. 5, 6) . Then, the assay was used to perform mediumthroughput/high-throughput screening campaigns using a set of 18,239 compounds and a set of 15,744 plant extracts and fractions. Assay analytical parameters were systematically controlled to ensure good data quality. The 100% control (%CTL) was defined with cells treated with 500 nM epoxomicin, and other %CTLs were calculated as follows: %CTL = 100 -(luminescent signal with tested condition/luminescent signal with 500 nM epoxomicin) × 100. Signals superior to 4% CTL were considered as hits (99.99% confidence level). Mean %CTL = 1.3%; hits = 24; hit rate = 0.13%.
During the assay development process, we have shown that, for epoxomicin concentrations superior to 1 µM, we observed a significant compound efficacy decrease ( Fig. 5) and assumed that this effect could be linked to epoxomicin-induced toxicity toward the DLD-1 4Ub-Luc cell line. Bortezomib also showed cytotoxic effects toward several human cancer cell lines for longer incubation time. 31 It was then clear that validated proteasome inhibitors presented cytotoxic properties that could interfere in the assay and lead to false-negative results. To estimate the amount of interfering responses that could occur during the screening, we tested 1536 randomly selected plant extracts and fractions corresponding to 384 plants and plant parts on the luciferase activity of DLD-1 4Ub-Luc cells. Cells were previously treated with 100 nM epoxomicin to detect the interfering effect of these extracts in a proteasome-blocked cellular background. Eight extracts and fractions, obtained from 4 plants and representing an interference rate of 0.52%, were identified. Three of these plants-Morus mongolica, 32 Uvaria chamae, 33 and Parquetina nigrescens 34 -were shown to contain cytotoxic molecules. The effect of these 3 plants on DLD-1 4Ub-Luc cell line viability was then assessed with an MTT assay and showed that only extracts 5, 6, and 7, from P. nigrescens, presented a significant toxicity (Fig. 6) , indicating that the interferences observed after this preliminary screening are partially associated with compound toxicity. Although bioluminescence presents a low level of unspecific responses compared to fluorescence, 22,35 the 3 interfering and nontoxic extracts could inhibit the luciferase activity, as already observed for proteasome inhibitors. 36 Finally, we estimated that the very limited 0.52% signal-lowering interference rate was partially linked to cell toxicity of plant extracts and fractions and did not prevent larger screening campaign achievement. The hit rates of the ubiquitin-proteasome pathway screenings were found to be different between chemical compounds and plant samples, with values of 0.13% and 0.49%, respectively ( Figs. 7, 8) . These rate differences could be explained by the fact that each plant extract or fraction contains several detectable secondary metabolites, 37 bringing, in theory, the total number of tested molecules to a much higher number than the 15,744 screened samples. The confirmation of these primary screening hits showed very good confirmation rates of 88% and 85% for molecules and natural sources, respectively. Finally, 21 molecules and 66 extracts and fractions were shown to be active on the ubiquitin-proteasome pathway. To validate whether this screening process could lead to the discovery of active molecules extracted from plants, we selected, as an example, the P. angulata L. aerial part active methanol extract and performed an activityguided fractionation. P. angulata L. (Solanaceae) is a common annual herb from tropical areas presenting immunomodulation, antimicrobial, and antitumor biological activities. [38] [39] [40] Fractions were produced from the initial methanol extract by liquid/liquid extraction followed by several chromatography purifications, and physalin B and C were identified ( Fig. 9) .
Physalins occur mainly in the Physalis species (Solanaceae). 41 In previous work, some physalins have demonstrated cytotoxic activities on various cell lines. 38 The dose-dependent determination of the ubiquitin-proteasome pathway inhibition was done for both compounds. The EC 50 values were calculated to 3.8 and 4.4 µM with 37 and 34 maximum %CTL efficacy for physalin B and C, respectively (100% CTL is obtained for a 500-nM epoxomicin concentration).
These compounds were then tested for endogenous ubiquitinated protein accumulation in a cell-based Western blot assay. Results indicated that, for both molecules, an accumulation of ubiquitin is observed for concentrations up to 5 µM (Fig. 10) , confirming the inhibition of the ubiquitinated protein degradation initially observed. The ability of the screening assay to identify active compounds from natural sources through our HTS and activity fractionation processes was then demonstrated. We can therefore consider that the HTS assay is functionally validated.
Unlike the majority of assays used to screen proteasome inhibitors, essentially based on the in vitro enzymatic cleavage of fluorescent substrates, 20,21 this approach could identify compounds that block the proteasome catalytic function and also those interfering with upstream steps of the ubiquitin-proteasome pathway. However, due to the artificial ubiquitination reaction, the assay can only address steps located downstream of the ubiquitination process itself, like the binding to the 19S regulatory particle, the ubiquitin chain removal by the metalloisopeptidase Rpn11, and the translocation into the 20S core particle.
Physalin B and C ubiquitin-proteasome pathway inhibition has not been reported yet, but physalin B has been shown to inhibit phorbol 12-myristate 13-acetate (PMA)-induced nuclear factor kappa B (NF-κB) activation in an interleukin-6 promoterdependent luciferase expression model. 42 Similar NF-κB inhibitory activities have been reported with bortezomib. By analogy, it is likely that the NF-κB inhibitory activity of physalin B is derived from its interference with the proteasome pathway, as reported here. Our data thus provide significant new advances for a better understanding of the mechanism of action of this secosteroid. Physalin B and C warrant further investigation as proteasome-targeted anticancer agents.
In conclusion, we have developed a novel ubiquitin-proteasome pathway assay in 96-and 384-well plate formats and shown that it can be used in the HTS of chemical compounds and plant extracts with good sensitivity, precision, and accuracy. An active extract from the P. angulata L. plant has been identified and enabled the purification of physalin B and C compounds, which also induced the accumulation of endogenous ubiquitinated proteins. This luminescent assay format should offer the same advantages for other natural sources, such as marine or micro-organisms, and is not limited to the identification of catalytic inhibitors of the proteasome complex but could also detect compounds and extracts active on the ubiquitinated protein processing pathway.
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